Premium
Evidence‐based update on Australasian pharmaceutical prescribing approaches for recurrent vulvovaginal candidiasis
Author(s) -
Bradfield Strydom Moira,
Walpola Ramesh Lahiru,
Khan Sohil,
Ware Robert S.,
Tiralongo Evelin
Publication year - 2021
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/ajo.13376
Subject(s) - vulvovaginal candidiasis , clarity , medicine , consistency (knowledge bases) , evidence based practice , clinical practice , intensive care medicine , dermatology , alternative medicine , family medicine , computer science , pathology , biology , antifungal , biochemistry , artificial intelligence
Recurrent vulvovaginal candidiasis (RVVC) is a subtype of vulvovaginal candidiasis, with debilitating effects on physical and emotional well‐being affecting up to 10% of Australian women. Current evidence suggests that the induction and maintenance approach for RVVC is not particularly effective with post‐treatment relapse rates as high as 57%. Frequently accessed Australasian RVVC prescribing resources and guidelines were examined showing a variety of adaptations of current evidence‐based induction and maintenance therapies, making it difficult to select best treatment in clinical practice. The ways to introduce more clarity and consistency into these guidelines are outlined.